E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Local anaesthesia prior to surgical wound debridement |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10002091 |
E.1.2 | Term | Anaesthesia |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Assessment of the safety and pharmacokinetics (the characteristic interactions of a drug and the body in terms of its absorption, distribution, metabolism, and excretion) of Tri-Solfen, when administered topically to leg ulcers |
|
E.2.2 | Secondary objectives of the trial |
To assess the time taken to achieve clinical acceptable surface anaesthesia of the ulcer, prior to surgical debridement (removal of dead tissue with a sharp blade) with Tri-Solfen To investigate the duration and quality of post-debridement pain relief following application of a single dose of Tri-Solfen administered on completion of surgical wound debridement vs standard of care post-debridement analgesia To assess the level of anaesthesia achieved during surgical wound debridement, when Tri-Solfen is administered prior to surgical wound debridement, and on completion of the procedure. To investigate the impact on the healing trajectory of leg ulcers following applications of Tri-Solfen.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients over 18 years with a leg ulcer of venous, arterial or mixed aetiology, requiring surgical debridement to remove slough, necrotic or unhealthy tissue and who provide written informed consent. Study wound of 2-30 cm2 surface area and present for 1-60 months. Presence of acute, non-cyclic pain experienced by the patient following previous debridement. Pain score should be >50mm on a 100mm visual analogue scale at baseline assessment (prior to application of treatment).
|
|
E.4 | Principal exclusion criteria |
Patients with an acute or chronic infectious skin disease. Wound bed with exposed bone, tendon or fascia. Patients with any anaesthetic allergy or intolerance to local anaesthetics or hypersensitivity to any of the ingredients of the Tri-Solfen or EMLA product. Patients with cellulitis and/or osteomyelitis. Patients with porphyria. Patients with abnormal thyroid function including thyrotoxicosis. Patients with established ventricular fibrillation, cardiac dilation, coronary insufficiency, including angina, organic brain disease or atherosclerosis. Patients with clinically significant hepatic or renal insufficiency. Patients receiving more than 2 weeks treatment with immunosuppressive agents in the past 3 months. Patients receiving oral corticosteroid theapy or topical corticosteroid on the leg where the reference ulcer is located. Any investigational drug use within 30 days. Severe malnutrition as judged by the Investigator. Patients who, in the opinion of the Investigator have an existing condition that would compromise their participation. Patients who have, or are suspected of having any underlying or skin malignancy or who have received treatment for any active malignancy, apart from non-melanomatic skin cancer, within 3 months prior to treatment. History of radiation at the study site. Any other conditions that could impede wound healing. Patients receiving concomitant medicines including, Carbemazepines, Rifampicin, Phenytoin, Griseofulvin, Phenobabitone and Sulphonylureas. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
An assessment of the safety and pharmacokinetcis of Tri-Solfen, when administered topically to leg ulcers |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
1) To assess the time taken to achieve clinically acceptable surface anaesthesia of the ulcer, prior to surgical wound debridement with Tri-Solfen. 2)To investigate the duration and quality of post-operative pain relief following application of a single dose of Tri-Solfen administered on completion of wound debridement vs standard of care (post-operative analgesia) 3) To assess the levels of anaesthesia achieved during surgical wound debridement, when Tri-Solfen is administered prior to surgical debridement, and on completion of the surgical procedure. 4) To investigate the impact on the healing trajectory of leg ulcers following applications of Tri-Solfen. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 2 |